share_log

Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq

Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq

Invizyne Technologies宣佈提交擬議在納斯達克發行和上市的註冊聲明
GlobeNewswire ·  02/12 21:00

Monrovia, CA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") ­– today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") for the sale of its common stock in a firm commitment public offering.

加利福尼亞州蒙羅維亞,2024年2月12日(GLOBE NEWSWIRE)——酶基生物製造系統的領先設計師、MDB Capital Holdings, LLC(納斯達克股票代碼:MDB)(“MDB”)的子公司Invizyne Technologies, Inc. 今天宣佈,已就出售其普通股向美國證券交易委員會(“SEC”)提交了S-1表格的註冊聲明堅定承諾的公開發行。

The offering shall be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million. Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol "IZTC."

本次發行將發行430萬股普通股,每股價格爲4.00美元,總收益爲1,720萬美元。Invizyne已申請在納斯達克股票市場上市,股票代碼爲 “IZTC”。

Public Ventures, LLC will be acting as the underwriter and sole book manager for the proposed offering. Digital Offering, LLC will be acting as the qualified independent underwriter. Public Ventures, LLC is a subsidiary of MDB and an affiliate of Invizyne.

Public Ventures, LLC將擔任擬議發行的承銷商和唯一賬面經理。Digital Offering, LLC將擔任合格的獨立承銷商。Public Ventures, LLC是MDB的子公司,也是Invizyne的子公司。

In allocating the shares to be sold, Public Ventures, LLC intends to give preference to holders of MDB Class A Shares, after which it will give preference to the other beneficial shareholders of MDB and then of Invizyne. To the extent these foregoing groups do not purchase all the available shares, including the overallotment, then shares will be sold to other persons making an indication for purchase of shares through their respective brokers or dealers.

在分配待售股份時,Public Ventures, LLC打算給予MDBAA類股票的持有人優先權,之後它將優先考慮MDB和Invizyne的其他受益股東。如果上述團體未購買包括總配股在內的所有可用股份,則股票將通過各自的經紀人或交易商出售給表示購買股票的其他人。

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

與這些證券有關的註冊聲明已向美國證券交易委員會提交,但尚未生效。在註冊聲明生效之前,不得出售這些證券,也不得接受買入要約。本新聞稿不構成出售要約或徵求購買此處任何證券的要約,在根據任何此類州或司法管轄區的證券法進行註冊或獲得資格認證之前,在任何州或司法管轄區出售此類證券是非法的,也不應在任何州或司法管轄區出售這些證券。

A copy of the prospectus related to the offering and included in the registration statement, when available, may be obtained by visiting the SEC website or by emailing Invizyne's Investor Relations department at IR@invizyne.com.

與本次發行有關幷包含在註冊聲明中的招股說明書的副本(如果有)可以通過訪問美國證券交易委員會網站或發送電子郵件至Invizyne的投資者關係部門獲得,地址爲 IR@invizyne.com。

About Invizyne Technologies, Inc.

關於 Invizyne Technologies

Invizyne Technologies, Inc., a subsidiary of MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") (), is an enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after chemicals. The management of Invizyne believes that the Invizyne biomanufacturing platform, known as SimplePath, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. The objective for SimplePath platform is to enable the efficient production of a diverse range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. The SimplePath platform not only can maximize the value of these resources but also will contribute to the development of novel chemical compounds that should open new markets and business opportunities.

Invizyne Technologies, Inc. 是MDB Capital Holdings, LLC(納斯達克股票代碼:MDB)()的子公司,是一家總部位於加利福尼亞州蒙羅維亞的酶基生物製造技術公司。Invizyne 正在重新定義生物製造,利用無細胞、多步驟、基於酶的系統將自然或可再生資源高效轉化爲備受追捧的化學品。Invizyne的管理層認爲,名爲SimplePath的Invizyne生物製造平台將成爲當前化合物生產方法(通常是化學合成、自然提取和合成生物學)的重要替代方案。SimplePath 平台的目標是實現各種化學品的高效生產,包括藥品、燃料、材料、食品添加劑和新型化合物。SimplePath平台不僅可以最大限度地提高這些資源的價值,而且還將爲新型化合物的開發做出貢獻,這將開闢新的市場和商機。

For more information, please visit

欲了解更多信息,請訪問

Media contacts: press@invizyne.com

媒體聯繫人:press@invizyne.com

Partnership contacts: partners@invizyne.com

合作伙伴聯繫人:partners@invizyne.com

Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

前瞻性陳述
本新聞稿包含 “前瞻性陳述”。這些前瞻性陳述自首次發佈之日起作出,基於當前的預期、估計、預測和預測以及管理層的信念和假設。諸如 “期望”、“預期”、“應該”、“相信”、“希望”、“目標”、“項目”、“目標”、“估計”、“潛力”、“預測”、“可能”、“可能”、“打算”、“應該” 和這些術語的變體或這些術語和類似表述的否定詞旨在識別這些前瞻性陳述。

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.

前瞻性陳述受許多風險和不確定性的影響,其中許多風險和不確定性涉及Invizyne無法控制的因素或情況。由於多種因素,Invizyne的實際業績可能與前瞻性陳述中陳述或暗示的業績存在重大差異。本新聞稿中包含的前瞻性陳述代表了截至本新聞稿發佈之日Invizyne的觀點。Invizyne預計,隨後的事件和事態發展將導致其觀點發生變化。無論是由於新信息、未來事件還是其他原因,Invizyne都沒有意圖或義務更新或修改任何前瞻性陳述。在本新聞稿發佈之日之後的任何日期,都不應依賴這些前瞻性陳述來代表Invizyne的觀點。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論